?????? ???????????? ????????? ?????? ??????????????? ?????? : ????????? ?????? ?????? ??????????????? ????????????

Department of Management EngineeringFirms participating in printer industries have invested their constrained resources into technology development in order to sustain their competitiveness in the industry. Considering the fast-changing market circumstances, each firm???s own investment decisions on technology portfolio may directly affect their performance. In this study, we analyzed patent data, namely number of forward citations and technological classification data (CPC). Using this data, the technological portfolio of a specific firm can be identified, which can further help our understanding on firms??? R&D investment strategies. Number of studies mainly focused on patent class combinations of individual technology level, but portfolios of patent class at a firm level have been understudied. In this study, we tracked the change of class composition within each firms??? technological patents??? portfolio and attempted to identify practical and theoretical implications to portfolio management. We utilized Entropy Index, Co-occurrence and cosine similarities measurements for each indicating diversification, patent scope and portfolio similarities within each patents??? classification subclasses. Additionally, performance evaluation of each portfolio is conducted using forward citation data. This paper shows that in-depth patent data analysis can allow us to explore deeper insights at various levels, individual technology, products and product lines, and firms sufficing different stories.ope

Strategic Knowledge Measurement and Management

Knowledge and intellectual capital are now recognized as vital resources for organizational survival and competitive advantage. A vast array of knowledge measures has evolved, spanning many disciplines. This chapter reviews knowledge measures focusing on groups of individuals (such as teams, business and organizations), as they reflect the stock or flow of knowledge, as well as enabling processes that enhance knowledge stocks and flows. The chapter emphasizes the importance of organizational value chains, pivotal talent pools and the link between knowledge and competitive success, in understanding the significance of today’s knowledge measures, and opportunities for future research and practice to enhance them

Patenting and industrial performance: the case of the machine tool industry

Using the case of an important capital goods industry the paper examines the impact of the national patent system on the performance of firms. Many theories attempt to explain the firms’ innovative behavior using the concepts of national and sectorial systems of innovation. The patent law plays a particularly important role in these systems. At the level of the firm its importance rests on the possibility to appropriate profits. An empirical analysis of a sample of the 49 largest international manufacturers of machine tools shows that patents are a superior mechanism for appropriating the returns on R&D in this industry. This is indicated by a strong positive relationship between the market value of the firm and its patenting activities. -- Am Beispiel einer wichtigen Investitionsgüterindustrie wird in diesem Beitrag der Einfluß nationaler Patentsysteme auf den Unternehmenserfolg untersucht. Zahlreiche Theorien gehen davon aus, daß das Innovationsverhalten von Unternehmen von nationalen und sektoralen Innovationssystemen beeinflußt wird. Das Patentrecht spielt in diesen Systemen eine wichtige Rolle. Auf der Unternehmensebene beeinflußt es die Möglichkeiten der Unternehmen Gewinne zu erzielen. Am Beispiel der 49 größten Unternehmen der internationalen Werkzeugmaschinenindustrie wird nachgewiesen, daß in diesem Industriezweig Patente ein wichtiges Instrument zur Erzielung von Gewinnen darstellen. Dies zeigt sich besonders deutlich an der engen positiven Beziehung, die zwischen dem Marktwert der Unternehmen und ihrem Patentierverhalten empirisch festgestellt wurde.

Global Competitiveness in Pharmaceuticals: A European Perspective

The report examines the competitive position of the European pharmaceutical companies and industries, and compares them with the pharmaceutical companies and industries in other parts of the world, particularly the US. Over the last two decades, the industry has experienced some important structural changes, mainly driven by technological and institutional shocks that have affected all the stages of its value chain. In turn, this has led to changes in firms' organisation and in market structure, within domestic markets, regionally, and globally. The main finding of the report is that the European industry has indeed been losing competitiveness as compared to the USA, although there are large differences and trends across European countries. As a whole, Europe is lagging behind in its ability to generate, organise, and sustain innovation processes that are increasingly expensive and organisationally complex. In fact, one conclusion of the report is that the relative position of the US as a locus of innovation in pharmaceuticals has increased over the past decade compared to Europe. All in all, the report claims that the competitiveness of the European pharmaceutical industry is negatively affected by the persistence of insufficient degrees of competition and institutional integration, still centred on domestic and fragmented health care and research systems. Four sets of variables have been found to be relevant as sources of competitiveness and growth in pharmaceuticals: 1) The size and the structure of the biomedical education and research systems; 2) Some basic institutions governing labor markets for skilled researchers and managers, as well as corporate governance and finance; 3) Intellectual property rights and patent law; 4) The institutional settings in the regulation of health care systems and, moreover, the nature and intensity of competition on the final market. The data analysed in this report come from OECD, Eurostat, the European Patent Office, IMS Health and PHID (PHarmaceutical Industry Database) at the University of Siena

How Does Knowledge Transfer from Foreign Subsidiaries Affect Parent Companies' Innovative Capacity

The paper addresses reverse knowledge transfer (RKT) from foreign subsidiary to parent company. Specifically, it aims at investigating to what extent the effectiveness of such a transfer is influenced by: (i) the organizational mechanisms employed for transferring knowledge; (ii) the subsidiary’s role, its autonomy, and its relationships with the local context. The empirical analysis considers 162 transfers of best practices possessed by foreign subsidiaries and transferred back to their Italian parent companies. Results confirm that the impact of RKT on the parent company’s innovativeness is greater when: (i) person-based mechanisms are employed for transferring knowledge; (ii) subsidiaries are competence-creating; and (iii) knowledge developed by subsidiaries benefits from local external linkages.External linkages; organizational mechanisms; parent company's innovativeness; reverse knowledge transfer, subsidiary’s characteristics

Do Firms Benefit from Being Present in Multiple Technology Clusters? An Assessment of the Technological Performance of Biopharmaceutical Firms

Firms active in knowledge-intensive fields are increasingly organizing their R&D activities on an international scale. This paper investigates whether firms active in biotechnology can improve their technological performance by developing R&D activities in multiple technology clusters. Regions in the US, Japan and Europe, that host a concentration of biotechnology activity are identified as clusters. Fixed-effect panel data analyses with 59 biopharmaceutical firms (period 1995-2002) provides evidence for a positive, albeit diminishing (inverted-U shape) relationship between the number of technology clusters in which a firm is present and its overall technological performance. This effect is distinct from a mere multi-location effect.region, clusters, biotechnology, technology clusters

Do firms benefit from being present in technology clusters? Evidence from a panel of biopharmaceutical firms.

This paper investigates whether firms active in biotechnology can improve their technological performance by developing R&D activities in technology clusters. Regions that host a concentration of biotechnology activity are identified as technology clusters (level of US states, Japanese prefectures and European NUTS2 regions). A fixed effect panel data analysis on a set of 59 biopharmaceutical firms (period 1995-2002) provides evidence for a positive, albeit diminishing (inverted-U shape) relationship between the number of technology clusters in which a firm is present and its total technological performance. This effect is distinct from a mere multi-location effect.Cluster; Innovation; Biotechnology;

Innovation and venture capital exit performance

Venture capital is a potent source of R&D financing which contributes significantly to technological innovation output in the form of patented inventions. Scholars have argued that tighter protection of intellectual property rights reduces expropriation risks and encourages venture capitalists to invest in technology firms. Prior studies have showed that early stage technology investors give much weight to investment selection criteria related to innovation e.g. protection of intellectual property, platform and uniqueness. However, VC investors generally receive little on their investments until a liquidation event occurs – IPO and M&A (trade sale) exits define venture capital performance. A review of the literature indicates that few empirical studies have examined the influence of patented innovation on the exit performance of VC-backed technology firms. This paper seeks to address this specific knowledge gap in venture capital research and practice. It builds on resource-based view (RBV) theory which argues that technological innovation is an important strategic resource of the entrepreneurial firm that can attract VC investment, provide competitive advantage and produce superior performance. This study is based on matched data compiled from VentureXpertTM, DelphionTM and NBER/USPTO databases. The resulting unique and proprietary dataset consists of 1504 U.S. VC-backed exits across 7 technology sectors in the 20 years from 1980-2000, 961 IPOs and 543 M&As. The influence of technological innovation on the exit performance of VC-backed technology firms is examined. As predicted by RBV theory, technology firms engaged in patenting activity were found more likely to be associated with the more profitable IPO exit route, higher VC investment and exit value